| |
 |
ARTICLES 
|
|
| Alternative medicine: an attractive nuisance |
| JR Durant |
|
JCO Jan 1 1998: 1–2.
[PDF]
|
 |
| Which treatment for mantle-cell lymphoma patients in 1998? |
| B Coiffier |
|
JCO Jan 1 1998: 3–5.
[PDF]
|
|
|
Cancer patients use of nonproven therapy: a 5-year follow-up study |
| |
T Risberg, E Lund, E Wist, S Kaasa, and T Wilsgaard |
| |
JCO Jan 1 1998: 6–12.
[Abstract]
[PDF]
|
|
|
High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission |
| |
AS Freedman, D Neuberg, JG Gribben, P Mauch, RJ Soiffer, DC Fisher, KC Anderson, N Andersen, R Schlossman, M Kroon, J Ritz, J Aster, and LM Nadler |
| |
JCO Jan 1 1998: 13–18.
[Abstract]
[PDF]
|
|
|
MOPP/ABV hybrid chemotherapy for advanced Hodgkin's disease significantly improves failure-free and overall survival: the 8-year results of the intergroup trial |
| |
JH Glick, ML Young, D Harrington, RL Schilsky, T Beck, R Neiman, RI Fisher, BA Peterson, and MM Oken |
| |
JCO Jan 1 1998: 19–26.
[Abstract]
[PDF]
|
|
|
CHOP is the standard regimen in patients > or = 70 years of age with intermediate-grade and high-grade non-Hodgkin's lymphoma: results of a randomized study of the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Study Group |
| |
U Tirelli, D Errante, M Van Glabbeke, I Teodorovic, JC Kluin-Nelemans, J Thomas, D Bron, G Rosti, R Somers, V Zagonel, and EM Noordijk |
| |
JCO Jan 1 1998: 27–34.
[Abstract]
[PDF]
|
|
|
Expression of the adhesion molecule ICAM-1 in non-Hodgkin's lymphoma: relationship with tumor dissemination and prognostic importance |
| |
MJ Terol, A Lopez-Guillermo, F Bosch, N Villamor, MC Cid, C Rozman, E Campo, and E Montserrat |
| |
JCO Jan 1 1998: 35–40.
[Abstract]
[PDF]
|
|
|
Maintenance of remission with human recombinant interferon alfa-2a in patients with stages III and IV low-grade malignant non-Hodgkin's lymphoma. European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group |
| |
A Hagenbeek, P Carde, JH Meerwaldt, R Somers, J Thomas, R De Bock, JM Raemaekers, A van Hoof, C De Wolf-Peeters, and M van Glabbeke |
| |
JCO Jan 1 1998: 41–47.
[Abstract]
[PDF]
|
|
|
Autologous bone marrow transplantation for patients with relapsed or refractory diffuse aggressive non-Hodgkin's lymphoma: value of augmented preparative regimens--a Southwest Oncology Group trial |
| |
PJ Stiff, S Dahlberg, SJ Forman, AR McCall, SJ Horning, AP Nademanee, KG Blume, M LeBlanc, and RI Fisher |
| |
JCO Jan 1 1998: 48–55.
[Abstract]
[PDF]
|
|
|
Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia |
| |
ML Varterasian, RM Mohammad, DS Eilender, K Hulburd, DH Rodriguez, PA Pemberton, JM Pluda, MD Dan, GR Pettit, BD Chen, and AM Al-Katib |
| |
JCO Jan 1 1998: 56–62.
[Abstract]
[PDF]
|
|
|
High-dose chemotherapy for relapsed and refractory diffuse large B-cell lymphoma: mediastinal localization predicts for a favorable outcome |
| |
U Popat, D Przepiork, R Champlin, W Pugh, K Amin, R Mehra, J Rodriguez, S Giralt, J Romaguera, A Rodriguez, A Preti, B Andersson, I Khouri, D Claxton, M de Lima, M Donato, P Anderlini, J Gajewski, F Cabanillas, and K van Besien |
| |
JCO Jan 1 1998: 63–69.
[Abstract]
[PDF]
|
|
|
Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients |
| |
MM Cheung, JK Chan, WH Lau, W Foo, PT Chan, CS Ng, and RK Ngan |
| |
JCO Jan 1 1998: 70–77.
[Abstract]
[PDF]
|
|
|
Analysis of prognostic factors in newly diagnosed acute promyelocytic leukemia treated with all-trans retinoic acid and chemotherapy. Japan Adult Leukemia Study Group |
| |
N Asou, K Adachi, J Tamura, A Kanamaru, S Kageyama, A Hiraoka, E Omoto, H Akiyama, K Tsubaki, K Saito, K Kuriyama, H Oh, K Kitano, S Miyawaki, K Takeyama, O Yamada, K Nishikawa, M Takahashi, S Matsuda, S Ohtake, H Suzushima, N Emi, and R Ohno |
| |
JCO Jan 1 1998: 78–85.
[Abstract]
[PDF]
|
|
|
Randomized prospective clinical trial of high-dose epirubicin and dexrazoxane in patients with advanced breast cancer and soft tissue sarcomas |
| |
M Lopez, P Vici, K Di Lauro, F Conti, G Paoletti, A Ferraironi, R Sciuto, D Giannarelli, and CL Maini |
| |
JCO Jan 1 1998: 86–92.
[Abstract]
[PDF]
|
|
|
Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute |
| |
G Bonadonna, P Valagussa, C Brambilla, L Ferrari, A Moliterni, M Terenziani, and M Zambetti |
| |
JCO Jan 1 1998: 93–100.
[Abstract]
[PDF]
|
|
|
Use of breast-conserving surgery for treatment of stage I and stage II breast cancer |
| |
E Guadagnoli, JC Weeks, CL Shapiro, JH Gurwitz, C Borbas, and SB Soumerai |
| |
JCO Jan 1 1998: 101–106.
[Abstract]
[PDF]
|
|
|
Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer |
| |
P Ellis, I Smith, S Ashley, G Walsh, S Ebbs, M Baum, N Sacks, and J McKinna |
| |
JCO Jan 1 1998: 107–114.
[Abstract]
[PDF]
|
|
|
Germ-line BRCA1 mutations in women with sporadic breast cancer: clinical correlations |
| |
E Garcia-Patino, B Gomendio, M Provencio, JM Silva, JM Garcia, P Espana, and F Bonilla |
| |
JCO Jan 1 1998: 115–120.
[Abstract]
[PDF]
|
|
|
p53 protein accumulation predicts poor response to tamoxifen therapy of patients with recurrent breast cancer |
| |
EM Berns, JG Klijn, WL van Putten, HH de Witte, MP Look, ME Meijer-van Gelder, K Willman, H Portengen, TJ Benraad, and JA Foekens |
| |
JCO Jan 1 1998: 121–127.
[Abstract]
[PDF]
|
|
|
Clinical significance of molecular detection of carcinoma cells in lymph nodes and peripheral blood by reverse transcription-polymerase chain reaction in patients with gastrointestinal or breast carcinomas |
| |
M Mori, K Mimori, H Ueo, K Tsuji, T Shiraishi, GF Barnard, K Sugimachi, and T Akiyoshi |
| |
JCO Jan 1 1998: 128–132.
[Abstract]
[PDF]
|
|
|
Genetic counseling and testing for breast-ovarian cancer susceptibility: what do women want? |
| |
J Audrain, B Rimer, D Cella, J Garber, BN Peshkin, J Ellis, J Schildkraut, M Stefanek, V Vogel, and C Lerman |
| |
JCO Jan 1 1998: 133–138.
[Abstract]
[PDF]
|
|
|
Interpreting the significance of changes in health-related quality-of- life scores |
| |
D Osoba, G Rodrigues, J Myles, B Zee, and J Pater |
| |
JCO Jan 1 1998: 139–144.
[Abstract]
[PDF]
|
|
|
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience |
| |
D Curran, T Sahmoud, P Therasse, J van Meerbeeck, PE Postmus, and G Giaccone |
| |
JCO Jan 1 1998: 145–152.
[Abstract]
[PDF]
|
|
|
Phase I trial of weekly paclitaxel in advanced lung cancer |
| |
W Akerley, M Glantz, H Choy, V Rege, S Sambandam, P Joseph, L Yee, B Rodrigues, P Wingate, and L Leone |
| |
JCO Jan 1 1998: 153–158.
[Abstract]
[PDF]
|
|
|
Phase I study of docetaxel with concomitant thoracic radiation therapy |
| |
AM Mauer, GA Masters, DJ Haraf, PC Hoffman, SM Watson, HM Golomb, and EE Vokes |
| |
JCO Jan 1 1998: 159–164.
[Abstract]
[PDF]
|
|
|
Phase I trial of retroviral-mediated transfer of the human MDR1 gene as marrow chemoprotection in patients undergoing high-dose chemotherapy and autologous stem-cell transplantation |
| |
C Hesdorffer, J Ayello, M Ward, A Kaubisch, L Vahdat, C Balmaceda, T Garrett, M Fetell, R Reiss, A Bank, and K Antman |
| |
JCO Jan 1 1998: 165–172.
[Abstract]
[PDF]
|
|
|
Preclinical and clinical studies of bone marrow uptake of fluorine-1- fluorodeoxyglucose with or without granulocyte colony-stimulating factor during chemotherapy |
| |
Y Sugawara, SJ Fisher, KR Zasadny, PV Kison, LH Baker, and RL Wahl |
| |
JCO Jan 1 1998: 173–180.
[Abstract]
[PDF]
|
|
|
Phase I trial and pharmacokinetic study of pyrazoloacridine in children and young adults with refractory cancers |
| |
SL Berg, SM Blaney, PC Adamson, M O'Brien, DG Poplack, C Arndt, J Blatt, and FM Balis |
| |
JCO Jan 1 1998: 181–186.
[Abstract]
[PDF]
|
|
|
Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer |
| |
R Bruno, D Hille, A Riva, N Vivier, WW ten Bokkel Huinnink, AT van Oosterom, SB Kaye, J Verweij, FV Fossella, V Valero, JR Rigas, AD Seidman, B Chevallier, P Fumoleau, HA Burris, PM Ravdin, and LB Sheiner |
| |
JCO Jan 1 1998: 187–196.
[Abstract]
[PDF]
|
|
|
Randomized prospective study of the benefit of adjuvant radiation therapy in the treatment of soft tissue sarcomas of the extremity |
| |
JC Yang, AE Chang, AR Baker, WF Sindelar, DN Danforth, SL Topalian, T DeLaney, E Glatstein, SM Steinberg, MJ Merino, and SA Rosenberg |
| |
JCO Jan 1 1998: 197–203.
[Abstract]
[PDF]
|
|
|
Radiation therapy for relapsed CNS germinoma after primary chemotherapy |
| |
TE Merchant, BJ Davis, JM Sheldon, and SA Leibel |
| |
JCO Jan 1 1998: 204–209.
[Abstract]
[PDF]
|
|
|
Intensive chemotherapy and bone marrow rescue for young children with newly diagnosed malignant brain tumors |
| |
WP Mason, A Grovas, S Halpern, IJ Dunkel, J Garvin, G Heller, M Rosenblum, S Gardner, D Lyden, S Sands, D Puccetti, K Lindsley, TE Merchant, B O'Malley, L Bayer, MM Petriccione, J Allen, and JL Finlay |
| |
JCO Jan 1 1998: 210–221.
[Abstract]
[PDF]
|
|
|
High-dose carboplatin, thiotepa, and etoposide with autologous stem- cell rescue for patients with recurrent medulloblastoma. Children's Cancer Group |
| |
IJ Dunkel, JM Boyett, A Yates, M Rosenblum, JH Garvin, Jr, BC Bostrom, S Goldman, LS Sender, SL Gardner, H Li, JC Allen, and JL Finlay |
| |
JCO Jan 1 1998: 222–228.
[Abstract]
[PDF]
|
|
|
Phase I dose escalation of 131I-metaiodobenzylguanidine with autologous bone marrow support in refractory neuroblastoma |
| |
KK Matthay, K DeSantes, B Hasegawa, J Huberty, RS Hattner, A Ablin, CP Reynolds, RC Seeger, VK Weinberg, and D Price |
| |
JCO Jan 1 1998: 229–236.
[Abstract]
[PDF]
|
|
|
Comparison between single-dose and divided-dose administration of dactinomycin and doxorubicin for patients with Wilms' tumor: a report from the National Wilms' Tumor Study Group |
| |
DM Green, NE Breslow, JB Beckwith, JZ Finklestein, PE Grundy, PR Thomas, T Kim, SJ Shochat, GM Haase, ML Ritchey, PP Kelalis, and GJ D'Angio |
| |
JCO Jan 1 1998: 237–245.
[Abstract]
[PDF]
|
|
|
Intermediate-dose intravenous methotrexate with intravenous mercaptopurine is superior to repetitive low-dose oral methotrexate with intravenous mercaptopurine for children with lower-risk B-lineage acute lymphoblastic leukemia: a Pediatric Oncology Group phase III trial |
| |
DH Mahoney, Jr, J Shuster, R Nitschke, SJ Lauer, N Winick, CP Steuber, and B Camitta |
| |
JCO Jan 1 1998: 246–254.
[Abstract]
[PDF]
|
|
|
Paclitaxel plus carboplatin in advanced carcinoma of the urothelium: an active and tolerable outpatient regimen |
| |
DJ Vaughn, SB Malkowicz, B Zoltick, R Mick, P Ramchandani, C Holroyde, B Armstead, K Fox, and A Wein |
| |
JCO Jan 1 1998: 255–260.
[Abstract]
[PDF]
|
|
|
Identification of clinical stage A nonseminomatous testis cancer patients at extremely low risk for metastatic disease: a combined approach using quantitive immunohistochemical, histopathologic, and radiologic assessment |
| |
I Leibovitch, RS Foster, KK Kopecky, P Albers, TM Ulbright, and JP Donohue |
| |
JCO Jan 1 1998: 261–268.
[Abstract]
[PDF]
|
|
|
Validity of predictions of residual retroperitoneal mass histology in nonseminomatous testicular cancer |
| |
EW Steyerberg, A Gerl, SD Fossa, DT Sleijfer, R de Wit, WJ Kirkels, N Schmeller, C Clemm, JD Habbema, and HJ Keizer |
| |
JCO Jan 1 1998: 269–274.
[Abstract]
[PDF]
|
|
|
Patient-reported symptoms after primary therapy for early prostate cancer: results of a prospective cohort study |
| |
JA Talcott, P Rieker, JA Clark, KJ Propert, JC Weeks, CJ Beard, KI Wishnow, I Kaplan, KR Loughlin, JP Richie, and PW Kantoff |
| |
JCO Jan 1 1998: 275–283.
[Abstract]
[PDF]
|
|
|
Radioimmunoscintigraphy with In-111-labeled capromab pendetide predicts prostate cancer response to salvage radiotherapy after failed radical prostatectomy |
| |
D Kahn, RD Williams, MK Haseman, NL Reed, SJ Miller, and J Gerstbrein |
| |
JCO Jan 1 1998: 284–289.
[Abstract]
[PDF]
|
|
|
Management of stage II seminoma |
| |
P Warde, M Gospodarowicz, T Panzarella, C Catton, J Sturgeon, M Moore, and M Jewett |
| |
JCO Jan 1 1998: 290–294.
[Abstract]
[PDF]
|
|
|
Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer |
| |
MJ O'Connell, JA Laurie, M Kahn, RJ Fitzgibbons, Jr, C Erlichman, L Shepherd, CG Moertel, WI Kocha, R Pazdur, HS Wieand, J Rubin, AM Vukov, JH Donohue, JE Krook, and A Figueredo |
| |
JCO Jan 1 1998: 295–300.
[Abstract]
[PDF]
|
|
|
Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. Meta-analysis Group In Cancer |
| |
|
| |
JCO Jan 1 1998: 301–308.
[Abstract]
[PDF]
|
|
|
ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy |
| |
R Metzger, CG Leichman, KD Danenberg, PV Danenberg, HJ Lenz, K Hayashi, S Groshen, D Salonga, H Cohen, L Laine, P Crookes, H Silberman, J Baranda, B Konda, and L Leichman |
| |
JCO Jan 1 1998: 309–316.
[Abstract]
[PDF]
|
|
|
Phase II trial of preoperative radiation therapy and chemotherapy for patients with localized, resectable adenocarcinoma of the pancreas: an Eastern Cooperative Oncology Group Study |
| |
JP Hoffman, S Lipsitz, T Pisansky, JL Weese, L Solin, and AB Benson, 3rd |
| |
JCO Jan 1 1998: 317–323.
[Abstract]
[PDF]
|
|
|
Influence of surgery on metachronous distant metastases and survival in rectal cancer |
| |
F Kockerling, MA Reymond, A Altendorf-Hofmann, O Dworak, and W Hohenberger |
| |
JCO Jan 1 1998: 324–329.
[Abstract]
[PDF]
|
|
|
Human papillomaviruses and associated malignancies |
| |
RM Alani and K Munger |
| |
JCO Jan 1 1998: 330–337.
[Abstract]
[PDF]
|
|
|
Current perspectives on radiation-induced breast cancer |
| |
PE Goss and S Sierra |
| |
JCO Jan 1 1998: 338–347.
[Abstract]
[PDF]
|
|
|
Tamoxifen and toremifene in breast cancer: comparison of safety and efficacy |
| |
AU Buzdar and GN Hortobagyi |
| |
JCO Jan 1 1998: 348–353.
[Abstract]
[PDF]
|
|
|
Should women take part in clinical trials in breast cancer? Issues and some solutions |
| |
J Cockburn, S Redman, and A Kricker |
| |
JCO Jan 1 1998: 354–362.
[Abstract]
[PDF]
|
|
| Pulmonary cavitating squamous cell carcinoma |
| FP Peters, FB Thunnissen, and GP ten Velde |
|
JCO Jan 1 1998: 363–364.
[PDF]
|
|
|
Training resource document for curriculum development in medical oncology. Adopted on February 20, 1997 by the American Society of Clinical Oncology |
| |
|
| |
JCO Jan 1 1998: 372–379.
[Abstract]
[PDF]
|
|
| Registry results and high-dose therapy |
| PM Ravdin, NS Callander, and GN Hortobagyi |
|
JCO Jan 1 1998: 387–388.
[PDF]
|
|
| Survival benefit in melanoma |
| BF Cole, RD Gelber, and JM Kirkwood |
|
JCO Jan 1 1998: 388–389.
[PDF]
|
|
| Influence of surgical resection on adjuvant therapy and outcome |
| M Benesch and C Urban |
|
JCO Jan 1 1998: 389–390.
[PDF]
|
|
| Secrecy for data monitoring committees: inferior ethics, bad policy |
| RJ Wells |
|
JCO Jan 1 1998: 390–391.
[PDF]
|
|
| Radiation in pediatric Hodgkin's disease |
| SS Donaldson and KR Lamborn |
|
JCO Jan 1 1998: 391–393.
[PDF]
|
|
| Radiation in pediatric Hodgkin's disease [In Process Citation] |
| JJ Shuster and PW Gieser |
|
JCO Jan 1 1998: 393a.
[PDF]
|
|
| Methotrexate, homocysteine, and seizures |
| CT Quinn, JC Griener, T Bottiglieri, and BA Kamen |
|
JCO Jan 1 1998: 393b–394.
[PDF]
|
|
